OBJECTIVE To evaluate the emerging classes of antihyperglycemic agents that target the
incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help …

Incretin based therapies such as dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-
like peptide-1 receptor agonists (GLP-1Ra) are increasingly used for the treatment of Type 2 …

ContextPharmacotherapies that augment the incretin pathway have recently become
available, but their role in the management of type 2 diabetes is not well defined …

Type 2 diabetes mellitus is widely prevalent and is often coexistent with obesity. Many of the
available treatment options have side effects such as weight gain which often affect patient's …

Although newer treatments for type 2 diabetes (T2D) patients have produced continual
improvements in outcome, a large and growing population with prediabetes remains under …

What is known and Objective: Incretin‐based glucagon‐like peptide‐1 receptor agonists
(GLP‐1 RAs) and dipeptidyl peptidase‐4 (DPP‐4) inhibitor therapies provide glycaemic …

Aims To summarize evidence from and assess the quality of published systematic reviews
evaluating the safety, efficacy and effectiveness of incretin‐based medications used in the …

Incretin hormones are secreted in response to food ingestion and help manage glycemic
control by regulating insulin and glucagon release, slowing gastric emptying, and reducing …

Background Glucose homeostasis is the result of a complex interaction of a spectrum of
hormones, including insulin, glucagon, amylin, and the incretins. Incretins are released by …

Background Clinical trials comparing incretin-based therapies—glucagon-like peptide-1
receptor agonists (exenatide—twice daily and once weekly—and once-daily liraglutide) and …